10-K: ATI Physical Therapy's 10-K Filing Reveals Ongoing Financial Struggles and Strategic Shifts

ATI Physical Therapy's latest 10-K filing highlights continued financial challenges, including substantial doubt about its ability to continue as a going concern, alongside strategic efforts to improve operations and explore alternative liquidity options.

Summary

• ATI Physical Therapy's 10-K filing reveals significant financial difficulties, casting substantial doubt on the company's ability to continue as a going concern.
• The company has experienced negative operating cash flows and net losses, attributed to its capital structure and operational performance.
• ATI is actively pursuing strategies to improve financial results, including increasing clinical staffing, enhancing clinician productivity, boosting patient visit volumes, and controlling costs.
• The company is also exploring alternative liquidity sources, such as raising additional debt or equity capital, disposing of assets, and considering other strategic options.
• Recent developments include the delisting of the company's Class A common stock from the NYSE and the termination of a tender offer due to unmet conditions.
• The company issued $26.0 million of 2L Notes in March 2025, convertible into common stock at $1.35 per share, and adjusted the conversion price for existing 2L Notes and Series B Preferred Stock to the same rate.
• ATI has terminated the registration of its common stock and public warrants under Section 12(g) of the Exchange Act, suspending its reporting obligations.
• As of December 31, 2024, ATI operated 866 clinics in 24 states, along with 16 managed clinics.
• The company observed stabilization in retention levels during 2024 and 2023 amid a tight labor market.
• Approximately 22.2% of the company's net patient revenue was derived from Medicare and Medicaid in 2024.
• The company anticipates a 2.8% reduction in Medicare reimbursement rates in 2025, unless revised by federal measures.
• Approximately 58.7% of ATI's net patient revenue was derived from commercial payors in 2024.
• Approximately 11.8% of ATI's net patient revenue was derived from workers compensation payors in 2024.
• The company reported a net loss of $54.0 million for the year ended December 31, 2024.
• The company's ability to utilize its net operating loss carryforwards may be limited due to ownership changes.

Sentiment

Score: 3

Explanation: The document paints a concerning picture of ATI's financial health, with significant challenges and uncertainties surrounding its future. While there are some positive initiatives, the overall tone is negative due to the going concern warning and other risk factors.

Positives

• The company is actively pursuing strategies to improve financial results, including increasing clinical staffing, enhancing clinician productivity, and controlling costs.
• ATI observed stabilization in retention levels during 2024 and 2023 amid a tight labor market.
• Net patient revenue per visit increased $2.26, or 2.1%, to $109.08 for the year ended December 31, 2024 compared to $106.82 for the year ended December 31, 2023.
• Same clinic revenue growth rate was 9.1%.

Negatives

• ATI Physical Therapy faces substantial doubt about its ability to continue as a going concern due to negative operating cash flows and net losses.
• The company terminated the registration of its common stock and public warrants under Section 12(g) of the Exchange Act, suspending its reporting obligations.
• The company anticipates a 2.8% reduction in Medicare reimbursement rates in 2025, unless revised by federal measures.
• The company reported a net loss of $54.0 million for the year ended December 31, 2024.
• The company's ability to utilize its net operating loss carryforwards may be limited due to ownership changes.

Risks

• The company's liquidity position raises substantial doubt about its ability to continue as a going concern.
• Failure to comply with debt covenants could result in the acceleration of debt obligations.
• Decreases in Medicare reimbursement rates may adversely affect financial results.
• The company operates in a competitive industry and may not be able to compete effectively.
• The company may be unable to attract or retain clinical or corporate talent.
• Rapid technological change presents significant risks and challenges.
• The company may be subject to legal proceedings, which are expensive and could divert management attention.
• Risks associated with securities trading on the OTC Pink Open Market and termination of the registration of common stock under Section 12(g) of the Exchange Act and the suspension of reporting obligations under Section 15(d) of the Exchange Act.

Future Outlook

The company plans to continue its efforts to improve its operating results and cash flow through increases to clinical staffing levels, improvements in clinician productivity, increases in patient visit volumes, referrals and rate per visit and controlling costs and capital expenditures.

Industry Context

The outpatient physical therapy market is highly fragmented, rapidly evolving and highly competitive with few financial barriers to enter the industry. Competition within the industry may intensify in the future as existing competitors and new entrants introduce new physical therapy services and platforms and consolidation in the healthcare industry continues.

Comparison to Industry Standards

• The document mentions competition from national and regional physical therapy providers, physician-owned practices, individual practitioners, and vertically integrated hospital systems.
• It also notes that the outpatient physical therapy market is rapidly evolving and subject to vertical integration, which could reduce the market opportunity for ATI's services.
• The document does not provide specific comparisons to industry standards or benchmarks in terms of financial performance, operational efficiency, or market share.

Management Changes

Legal Proceedings

• The parties to the Federal Securities, Delaware, and Federal Derivative Litigations reached agreement to resolve all four cases.
• The parties agreed to settle all of the putative class (or direct) claims and all of the derivative claims in these actions for $26.5 million, in the aggregate (to be paid entirely by insurance), which received preliminary approval from the court in the Federal Securities Litigation on May 21, 2024, and from the court in the Federal Derivative Litigation on June 11, 2024.
• A final approval hearing was held on September 24, 2024, and the settlements were finally approved.
• The appeals period expired 30 days later, and the settlement funds were disbursed in accordance with the terms of the stipulation.

Related Party Transactions

• Knighthead, Marathon, and Onex collectively exchanged a principal amount of $100.0 million of Senior Secured Term Loan for $100.0 million of 2L Notes stapled with a number of shares of Series B Preferred Stock.
• On the Closing Date, an additional $3.2 million of 2L Notes with stapled Series B Preferred Stock were issued among the same related parties as part of the First Amendment to the Second Lien Note Purchase Agreement.
• On October 2, 2024, the Company entered into the Second Amendment to Note Purchase Agreement, pursuant to which the Company issued $10.5 million of Second Lien Loans, of which half was issued to Knighthead and half was issued to Marathon.
• On March 3, 2025, the Company entered into the Fourth Amendment to Note Purchase Agreement, pursuant to which the Company issued $26.0 million of Fourth Amendment 2L Notes to Knighthead, MAM, Onex and Caspian Capital.

Stakeholder Impact

• Shareholders: Face significant risks due to the company's financial instability and potential dilution.
• Employees: May experience uncertainty due to potential cost-cutting measures and restructuring.
• Customers: Could be affected by changes in service quality or clinic closures.
• Creditors: Face increased risk of default or restructuring of debt obligations.

Next Steps

• The company plans to continue its efforts to improve its operating results and cash flow through increases to clinical staffing levels, improvements in clinician productivity, increases in patient visit volumes, referrals and rate per visit and controlling costs and capital expenditures.
• The company is considering raising additional debt and/or equity capital, disposal of assets, and/or other strategic alternatives to improve its business, results of operations and financial condition.

Key Dates